Overview
NAMS market data
Price History
NAMS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.72 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.08 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,644.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $23.05 – $42.21 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.2B · P/B 5.82 · P/S 447.70.
Company News
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50Benzinga · Aug 6, 2026, 5:46 PM
NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M EstimateBenzinga · Aug 5, 2026, 11:25 AM
NewAmsterdam Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Recommending Marketing Authorization For Ubeslo, Evlarco To Treat Primary HypercholesterolemiaBenzinga · Jul 24, 2026, 12:01 PM
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51Benzinga · Jun 30, 2026, 3:35 PM
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific SessionsGlobenewswire Inc · Jun 3, 2026, 12:15 PM
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in JuneGlobenewswire Inc · May 28, 2026, 12:15 PM